News | March 14, 2026
Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
From material selection to cooling tower management, every small decision affects long-term equipment reliability
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
Subscribe To Our Newsletter & Stay Updated
